Engineered liposomes for vascular drug delivery
The patent refers to engineered nanoliposomes and their production process to make them suitable for a targeted therapy of atherosclerosis. These nanovesicles, are produced starting from phosphatidylcholine, can be used as carriers for monoclonal antibodies. They are also engineered on their surface by the deposition of polyanions and/or polycations that allow the immobilization of highly specific antibodies for the atherosclerotic plaque.
The engineered nanoliposomes are considered as an innovative tool for the treatment of atherosclerosis. Unlike traditional therapy, this nano-formulation is based on antibodies that selectively block specific cellular pathways in the early-stage atherosclerosis. Furthermore, contrary to the systemic administration of antibodies, this therapeutic strategy will reduce possible side-effects since the active molecules will be released exclusively where they will be necessary. Nanoliposomes are produced by lipidic film hydration technique, a method easy to scale-up, useful to encapsulate therapeutic antibodies with good efficiency. Polyanions and/or polycations are deposed on the external surface of the vesicles in order to fix specific antibodies for the atherosclerotic plaque. Nanoliposomes were studied on a laboratory scale in order to define their properties: the produced vesicles show a good particle size, an optimal stability, a good encapsulation efficiency, and an adequate kinetic of release. Furthermore, the nano-suspensions are easily sterilizable, biocompatible, and hemocompatible.
- Targeted delivery;
- Encapsulation of therapeutic proteins;
- For modulating the inflammation related to the atherosclerotic plaque;
- For the regression of the atherosclerotic plaque.
- Easy implementation of nanoliposome production at an industrial level (scale-up);
- Good particle size;
- Optimal stability;
- Good encapsulation efficiency;
- Adequate kinetic of release;
- Sterilizable, biocompatible, and hemocompatible.